|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCFL5 |
Gene summary for TCFL5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCFL5 | Gene ID | 10732 |
| Gene name | transcription factor like 5 | |
| Gene Alias | CHA | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86TP4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10732 | TCFL5 | HCC1_Meng | Human | Liver | HCC | 6.88e-15 | 1.81e-02 | 0.0246 |
| 10732 | TCFL5 | HCC2_Meng | Human | Liver | HCC | 5.98e-03 | 2.94e-02 | 0.0107 |
| 10732 | TCFL5 | HCC1 | Human | Liver | HCC | 2.43e-02 | 1.67e+00 | 0.5336 |
| 10732 | TCFL5 | HCC2 | Human | Liver | HCC | 1.02e-04 | 1.42e+00 | 0.5341 |
| 10732 | TCFL5 | S028 | Human | Liver | HCC | 8.47e-08 | 2.60e-01 | 0.2503 |
| 10732 | TCFL5 | male-WTA | Human | Thyroid | PTC | 1.49e-04 | 6.49e-02 | 0.1037 |
| 10732 | TCFL5 | PTC06 | Human | Thyroid | PTC | 2.76e-06 | 9.94e-02 | 0.2057 |
| 10732 | TCFL5 | ATC12 | Human | Thyroid | ATC | 9.43e-07 | 1.31e-01 | 0.34 |
| 10732 | TCFL5 | ATC13 | Human | Thyroid | ATC | 8.98e-25 | 5.00e-01 | 0.34 |
| 10732 | TCFL5 | ATC4 | Human | Thyroid | ATC | 1.36e-11 | 1.64e-01 | 0.34 |
| 10732 | TCFL5 | ATC5 | Human | Thyroid | ATC | 5.27e-33 | 5.59e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| TCFL5 | INCAF | Colorectum | ADJ | PARP6,ICA1,LINC00476, etc. | 1.00e-01 |  |
| TCFL5 | ICAF | Colorectum | ADJ | PARP6,ICA1,LINC00476, etc. | 2.20e-01 | |
| TCFL5 | URO | Prostate | Tumor | CCL3L3,FAM134B,BMP3, etc. | 9.91e-02 |  |
| TCFL5 | SMC | Skin | cSCC | SCRN1,SERPINB1,TNS2, etc. | 1.51e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCFL5 | SNV | Missense_Mutation | c.1096N>A | p.Gly366Ser | p.G366S | Q9UL49 | protein_coding | tolerated(0.59) | possibly_damaging(0.738) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCFL5 | SNV | Missense_Mutation | rs763542036 | c.1415G>A | p.Arg472Gln | p.R472Q | Q9UL49 | protein_coding | tolerated(0.07) | benign(0.097) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| TCFL5 | insertion | Frame_Shift_Ins | novel | c.774_775insGTGGGAG | p.Leu259ValfsTer12 | p.L259Vfs*12 | Q9UL49 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| TCFL5 | deletion | Frame_Shift_Del | novel | c.1257_1269delNNNNNNNNNNNNN | p.Cys419Ter | p.C419* | Q9UL49 | protein_coding | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| TCFL5 | deletion | Frame_Shift_Del | novel | c.1053delN | p.Asp351GlufsTer4 | p.D351Efs*4 | Q9UL49 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TCFL5 | SNV | Missense_Mutation | novel | c.1282C>T | p.Pro428Ser | p.P428S | Q9UL49 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TCFL5 | SNV | Missense_Mutation | rs763542036 | c.1415N>A | p.Arg472Gln | p.R472Q | Q9UL49 | protein_coding | tolerated(0.07) | benign(0.097) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| TCFL5 | SNV | Missense_Mutation | rs778322425 | c.740N>T | p.Ala247Val | p.A247V | Q9UL49 | protein_coding | tolerated(0.1) | possibly_damaging(0.557) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TCFL5 | SNV | Missense_Mutation | rs767486884 | c.1042N>T | p.Arg348Cys | p.R348C | Q9UL49 | protein_coding | tolerated(0.06) | possibly_damaging(0.759) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TCFL5 | SNV | Missense_Mutation | c.1426N>A | p.Leu476Met | p.L476M | Q9UL49 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.916) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |